Lorena Simon-Gracia
Overview
Explore the profile of Lorena Simon-Gracia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Daly J, Simonetti B, Klein K, Chen K, Kavanagh Williamson M, Anton-Plagaro C, et al.
Science
. 2020 Oct;
370(6518):861-865.
PMID: 33082294
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), uses the viral spike (S) protein for host cell attachment and entry. The host protease...
12.
Lepland A, Asciutto E, Malfanti A, Simon-Gracia L, Sidorenko V, Vicent M, et al.
Mol Pharm
. 2020 May;
17(7):2518-2531.
PMID: 32421341
M2-like tumor-associated macrophages (M2 TAMs) play important roles in the resistance of tumors to immunotherapies. Selective depletion or reprogramming of M2 TAMs may sensitize the nonresponsive tumors for immune-mediated eradication....
13.
Diaz Bessone M, Simon-Gracia L, Scodeller P, Ramirez M, Lago Huvelle M, Soler-Illia G, et al.
J Nanobiotechnology
. 2019 Dec;
17(1):120.
PMID: 31812165
Background: Tamoxifen (Tam) is the most frequent treatment for estrogen receptor (ER) positive breast cancer. We recently showed that fibronectin (FN) leads to Tam resistance and selection of breast cancer...
14.
Saalik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A, et al.
J Control Release
. 2019 Jul;
308:109-118.
PMID: 31255690
Tumor-selective drug conjugates can potentially improve the prognosis for patients affected by glioblastoma (GBM) - the most common and malignant type of brain cancer with no effective cure. Here we...
15.
Asciutto E, Kopanchuk S, Lepland A, Simon-Gracia L, Aleman C, Teesalu T, et al.
J Phys Chem B
. 2019 Feb;
123(9):1973-1982.
PMID: 30768279
We recently identified a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically interacts with mouse CD206 to target CD206/MRC1-expressing tumor-associated macrophages in mice. Here, we report studies on the binding of...
16.
Simon-Gracia L, Hunt H, Teesalu T
Molecules
. 2018 May;
23(5).
PMID: 29772690
Over recent decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies-a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to...
17.
Simon-Gracia L, Scodeller P, Fuentes S, Vallejo V, Rios X, San Sebastian E, et al.
Oncotarget
. 2018 May;
9(27):18682-18697.
PMID: 29721153
Triple negative breast cancer (TNBC) is the deadliest form of breast cancer and its successful treatment critically depends on early diagnosis and therapy. The multi-compartment protein p32 is overexpressed and...
18.
Wonder E, Simon-Gracia L, Scodeller P, Majzoub R, Kotamraju V, Ewert K, et al.
Biomaterials
. 2018 Mar;
166:52-63.
PMID: 29544111
Cationic liposome-nucleic acid (CL-NA) complexes, which form spontaneously, are a highly modular gene delivery system. These complexes can be sterically stabilized via PEGylation [PEG: poly (ethylene glycol)] into nanoparticles (NPs)...
19.
Scodeller P, Simon-Gracia L, Kopanchuk S, Tobi A, Kilk K, Saalik P, et al.
Sci Rep
. 2017 Nov;
7(1):14655.
PMID: 29116108
Tumor-associated macrophages (TAMs) expressing the multi-ligand endocytic receptor mannose receptor (CD206/MRC1) contribute to tumor immunosuppression, angiogenesis, metastasis, and relapse. Here, we describe a peptide that selectively targets MRC1-expressing TAMs (MEMs)....
20.
Hunt H, Simon-Gracia L, Tobi A, Kotamraju V, Sharma S, Nigul M, et al.
J Control Release
. 2017 Jun;
260:142-153.
PMID: 28603028
Gastrointestinal and gynecological malignancies disseminate in the peritoneal cavity - a condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to improve therapeutic index of anticancer drugs...